ASCO '12 Abstract Dump: Cancer Stocks in Focus

Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting.

_

(AVEO)

(EXEL_)

_

(ARRY)

Among the most significant cancer drug data unveiled for the first time Wednesday night came from phase III studies conducted by Aveo Pharmaceuticals and Exelixis, and randomized phase II studies of drugs discovered by Array BioPharma.

Read the full story: http://hcp.lv/KlaVJ3

Source: The Street